Core Viewpoint - Viking Therapeutics, Inc. reported a wider-than-expected loss in Q3 2025, with shares showing a slight increase of about 1% since the last earnings report, outperforming the S&P 500 [1][3]. Financial Performance - The company reported a Q3 2025 loss of 81 cents per share, which was wider than the Zacks Consensus Estimate of a loss of 70 cents, and a significant increase from a loss of 22 cents per share in the same quarter last year [3]. - Viking Therapeutics has not generated any revenues as it currently has no approved products in its portfolio [3]. - Research and development (R&D) expenses rose to $90 million, compared to $22.8 million in the year-ago period, driven by higher costs related to clinical studies, manufacturing, and increased employee-related expenses [4]. - General and administrative expenses decreased to $8.6 million, down nearly 38% year over year, primarily due to lower legal and patent service costs and stock-related compensation expenses [5]. - As of September 30, 2025, the company had cash, cash equivalents, and short-term investments totaling $715 million, down from $808 million as of June 30, 2025 [5]. Market Reactions - Following the earnings release, there has been a downward trend in estimates revisions, with the consensus estimate shifting down by 19.23% [6]. - The stock currently has a poor Growth Score of F, a Momentum Score of D, and a Value Score of C, placing it in the middle 20% for the value investment strategy [7]. Outlook - Estimates for Viking Therapeutics have been trending downward, indicating a negative shift in market sentiment, with a Zacks Rank of 3 (Hold), suggesting an expectation of in-line returns in the coming months [8].

Helping to improve human health is one of the most important uses of AI. Insightful discussion with @TomMackenzieTV on Bloomberg Tech Europe of our great progress @IsomorphicLabs designing new drug candidates for challenging targets. https://t.co/WcxYvGfpsQ ...